(NYSE: OGN) Organon & Co's forecast annual revenue growth rate of -1.03% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 10%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.68%.
Organon & Co's revenue in 2025 is $6,403,000,000.On average, 3 Wall Street analysts forecast OGN's revenue for 2025 to be $1,611,842,778,050, with the lowest OGN revenue forecast at $1,603,067,313,981, and the highest OGN revenue forecast at $1,620,349,973,964. On average, 3 Wall Street analysts forecast OGN's revenue for 2026 to be $1,612,434,257,742, with the lowest OGN revenue forecast at $1,585,877,516,052, and the highest OGN revenue forecast at $1,631,875,186,622.
In 2027, OGN is forecast to generate $1,628,669,640,120 in revenue, with the lowest revenue forecast at $1,588,637,582,646 and the highest revenue forecast at $1,663,693,337,501.